ClinicalTrials.gg
CompletedNCT05293496Updated Oct 14, 2025

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of vobramitamab duocarmazine and lorigerlimab in Advanced Solid Tumor, Castration-Resistant Prostatic Cancer and Malignant Melanoma, sponsored by MacroGenics. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-14.

Sponsored by MacroGenics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States — 17 open to participants now, 23 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · United States.

Enrollment
30th of 42
31 · median 91
Started
2022
with 5 others
Phase 1
15 of 50
5 open now
Registered
28th of 50
by date
Lead sponsor
4 of 50
MacroGenics

Among the 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, this one is the 30th largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2022, is one of 15 in phase 1, and was the 28th registered.

Prostatic Neoplasms, Castration-Resistant

85 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 28 are open to participants now.

Browse Prostatic Neoplasms, Castration-Resistant studies →

Open to participants now

17 of the 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (88%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, or all of them as a file.
02

Study summary

Study CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab (MGD019). The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors including, but not limited to, metastatic castration-resistant prostate cancer (mCRPC), melanoma, pancreatic cancer, hepatocellular carcinoma (HCC), ovarian cancer, and renal cell carcinoma (RCC) will be enrolled.

Vobramitamab duocarmazine and lorigerlimab are administered separately on Day 1 of every 4-week (28-day) cycle at the assigned dose for each cohort. Participants who do not meet criteria for study drug discontinuation may receive study drugs for up to 2 years.

Tumor assessments are performed every 8 weeks (± 7 days) for the initial 6 months on study drugs, then every 12 weeks (± 21 days) until progressive disease (PD).

Participants will be followed for safety throughout the study. .

03

Conditions studied

  • Advanced Solid Tumor
  • Castration-Resistant Prostatic Cancer
  • Malignant Melanoma
  • Pancreatic Ductal Carcinoma
  • Hepatocellular Cancer
  • Epithelial Ovarian Cancer
  • Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Ability to provide and document and willing and able to comply with all study procedures.
  • Participants diagnosed with advanced solid tumors including but not limited to castration-resistant prostate cancer, melanoma, pancreatic cancer, hepatocellular carcinoma, ovarian cancer and renal cell carcinoma.
  • Participants have received approved therapies according to their diagnosis.
  • Participants must have an available tumor tissue sample. A fresh tumor may be performed if no archival sample is available.
  • performance status of less than or equal to 2.
  • of at least 12 weeks.
  • Evidence of measurable tumor for evaluation
  • Acceptable end organ function according to laboratory results.
  • Patients must agree to use highly-effective during the study, and not donate sperm or ova.

Exclusion criteria

Exclusion Criteria:

  • Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.
  • Another that required treatment within the past 2 years. Participants who have had curative therapy for non-melanomatous skin cancer, localized prostate cancer (Gleason score \< 6), or carcinoma in situ are eligible for the study.
  • Active viral, bacterial, or fungal infection requiring systemic treatment within 1 week of initiation of study drug. Participants are eligible after SARS CoV 2-related symptoms have fully recovered for ≥ 72 hours.
  • History of immunodeficiency. Participants with are eligible if they have a ≥ 300/µL, undetectable viral load, and maintained on antiretroviral therapy for a minimum of 4 weeks.
  • Prior autologous/allogeneic stem cell or tissue/solid organ transplant
  • Prior treatment with MGD009, enoblituzumab, or other B7-H3 targeted agents for cancer.
  • cardiovascular disease, lung compromise, venous insufficiency, or gastrointestinal disorders.
  • Participants with greater than Grade 1 peripheral neuropathy.
  • Participants who have a history of severe adverse events (AEs) from (anti-PD-1, anti-PD-L1, or CTLA-4 inhibitors). All other AEs from prior immune checkpoint inhibitors must be resolved to Grade 1 or less. Participants with any grade neurologic toxicity from prior immune checkpoint inhibitors are excluded.
  • Pleural effusion or ascites. Trace pleural or peritoneal fluid is not exclusionary.
  • History of Guillain-Barre syndrome, myasthenia gravis, or other sensory or motor neuropathies.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Cohort -1

    vobramitamab duocarmazine at dose level -1 and lorigerlimab intravenously (IV) every 4 weeks

    Biological: vobramitamab duocarmazine · Biological: lorigerlimab

  • Experimental
    Cohort 1

    vobramitamab duocarmazine at dose level 1 and lorigerlimab IV every 4 weeks

    Biological: vobramitamab duocarmazine · Biological: lorigerlimab

  • Experimental
    Cohort 2

    vobramitamab duocarmazine at dose level 1 and lorigerlimab IV every 4 weeks

    Biological: vobramitamab duocarmazine · Biological: lorigerlimab

  • Experimental
    Cohort 3

    vobramitamab duocarmazine at dose level 2 and lorigerlimab IV every 4 weeks

    Biological: vobramitamab duocarmazine · Biological: lorigerlimab

  • Experimental
    Cohort 4

    vobramitamab duocarmazine at dose level 3 and lorigerlimab IV every 4 weeks

    Biological: vobramitamab duocarmazine · Biological: lorigerlimab

  • Experimental
    Cohort 5

    vobramitamab duocarmazine at dose level 4 and lorigerlimab IV every 4 weeks

    Biological: vobramitamab duocarmazine · Biological: lorigerlimab

  • Experimental
    Cohort Expansion

    maximum tolerated dose of vobramitamab duocarmazine and lorigerlimab IV every 4 weeks

    Biological: vobramitamab duocarmazine · Biological: lorigerlimab

Interventions

  • Vobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3.

    Also known as: MGC018

  • Biologicallorigerlimab

    Lorigerlimab is a bispecific DART® molecule that binds PD-1 and CTLA-4.

    Also known as: MGD019

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 2 years

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 2 years

  3. Number of participants with AEs leading to study treatment discontinuation

    Time frame: Up to 2 years

Secondary outcomes

  1. Mean maximum observed concentration (Cmax) of vobramitamab duocarmazine

    Peak concentration of vobramitamab duocarmazine

    Time frame: Throughout the study, up to 2 years

  2. Mean maximum observed concentration (Cmax) of lorigerlimab

    Peak concentration of lorigerlimab

    Time frame: Throughout the study, up to 2 years

  3. Mean time to maximum concentration (Tmax) of vobramitamab duocarmazine

    Time at which peak concentration of vobramitamab duocarmazine is observed

    Time frame: Throughout the study, up to 2 years

  4. Mean time to maximum concentration (Tmax) of lorigerlimab

    Time at which peak concentration of lorigerlimab is observed

    Time frame: Throughout the study, up to 2 years

  5. Mean area under the concentration-time curve during the dosing interval (AUCtau) of vobramitamab duocarmazine

    Concentration of vobramitamab duocarmazine in the bloodstream during the 28-day dosing interval after dose administration

    Time frame: Throughout the study, up to 2 years

  6. Mean area under the concentration-time curve during the dosing interval (AUCtau) of lorigerlimab

    Concentration of lorigerlimab in the bloodstream during the 28-day dosing interval after dose administration

    Time frame: Throughout the study, up to 2 years

  7. Mean trough concentration of vobramitamab duocarmazine

    Concentration of vobramitamab duocarmazine at the end of a dosing interval

    Time frame: Day 1 of each cycle (every 4 weeks) up to 2 years.

  8. Mean trough concentration of lorigerlimab

    Concentration of lorigerlimab at the end of a dosing interval

    Time frame: Throughout the study, up to 2 years

  9. Number of participants who develop anti-drug antibodies (ADA) to vobramitamab duocarmazine

    Time frame: Throughout the study, up to 2 years

  10. Number of participants who develop ADA to lorigerlimab

    Time frame: Throughout the study, up to 2 years

  11. Objective response rate (ORR)

    Time frame: Assessed every 8 weeks for the first 6 months, then every 12 weeks for up to 2 years.

  12. Median progression free survival (PFS)

    PFS is defined as the time from the first dose date to the date of first documented PD or death from any cause, whichever occurs first.

    Time frame: Assessed every 8 weeks for the first 6 months, then every 12 weeks. Survival status is assessed approximately every 12 weeks after the last dose of study treatment until withdrawal of consent, lost to follow up, death, or end of the study, up to 2 years.

  13. Median duration of response (DoR)

    DoR is defined as the time from the date of initial response (CR or PR) to the date of first documented PD or death from any cause, whichever occurs first.

    Time frame: Assessed every 8 weeks for the first 6 months, then every 12 weeks for up to 2 years.

  14. Median overall survival (OS)

    OS is defined as the time from the first dose date to the date of death from any cause.

    Time frame: Survival status is assessed approximately every 12 weeks after the last dose of study treatment until withdrawal of consent, lost to follow up, death, or end of the study, up to 2 years

  15. Median radiographic PFS (rPFS) for mCRPC

    rPFS is defined as the time from the first dose of study drug to the first occurrence of radiographic PD of soft tissue lesions using RECIST v1.1, or appearance of ≥ 2 new bone lesions, or death from any cause

    Time frame: Assessed every 8 weeks for the first 6 months, then every 12 weeks for up to 2 years.

  16. Prostate-specific antigen (PSA) response rate for mCRPC

    PSA response is defined as ≥ 50% decline from baseline in PSA with confirmation at least 3 weeks later.

    Time frame: PSA is assessed every 4 weeks, up to 2 years while on treatment, then every 12 weeks for up to an additional 2 years in follow-up.

  17. Best PSA percent change from baseline for mCRPC

    Time frame: PSA is assessed every 4 weeks, up to 2 years while on treatment, then every 12 weeks for up to an additional 2 years in follow-up.

  18. Median time to PSA progression for mCRPC

    PSA progression is defined as an increase that is ≥ 25% and ≥ 2 ng/mL the baseline or lowest value observed, and which confirmed by a second value at least 3 weeks later.

    Time frame: PSA is assessed every 4 weeks, up to 2 years while on treatment, then every 12 weeks for up to an additional 2 years in follow-up.

  19. Median duration of PSA response for mCRPC

    DoR of PSA is defined as the time from the date of initial PSA response to the date of first documented PSA progression or death from any cause, whichever occurs first.

    Time frame: PSA is assessed every 4 weeks, up to 2 years while on treatment, then every 12 weeks for up to an additional 2 years in follow-up.

07

Study locations

10 sites
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
  • University of California, San Francisco
    San Francisco, California 94115, United States
  • Florida Cancer Specialists and Research Institute
    Sarasota, Florida 34232, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21287, United States
  • Weill Cornell Medicine
    New York, New York 10065, United States
  • Carolina BioOncology
    Huntersville, North Carolina 28078, United States
  • Stephenson Cancer Center, The University of Oklahoma
    Oklahoma City, Oklahoma 73104, United States
  • University of Pittsburgh Medical Center, Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • University of Virginia Comprehensive Cancer Center
    Charlottesville, Virginia 22908, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Jun 2025, 38 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2022
First posted
Mar 24, 2022
StartActual
Apr 19, 2022
Primary completionActual
Jun 24, 2025
CompletionActual
Aug 26, 2025
Last update
Oct 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05293496
Lead sponsor
MacroGenics
Responsible party
Sponsor
First posted
Mar 24, 2022
Start date
Apr 19, 2022
Primary completion
Jun 24, 2025
Completion
Aug 26, 2025
Last update
Oct 14, 2025

Study contacts

Denise Casey, M.D.
study director · MacroGenics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vobramitamab duocarmazine · Lorigerlimab

Start the discussion